Enhancement of SARS-CoV-2 vaccine-induced immunity by a Toll-like receptor 7 agonist adjuvant  

作　　者：Gen Li Meixing Yu Qiong Ke Jing Sun Yanwen Peng Chuanfeng Xiong Olivia Monteiro COVID-Infection and Immunity Investigation Group Jincun Zhao Andy P.Xiang 

机构地区：[1]Guangzhou Women and Children’s Medical Center,Guangzhou Medical University,Guangzhou,China [2]Center for Stem Cell Biology and Tissue Engineering,Key Laboratory for Stem Cells and Tissue Engineering,Ministry of Education,Sun Yat-sen University,Guangzhou,China [3]State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease,Guangzhou Institute of Respiratory Health,First Affiliated Hospital,Guangzhou Medical University,Guangzhou,China [4]Center for Biomedicine and Innovations,Faculty of Medicine,Macao University of Science and Technology,Macao,China [5]不详

出　　处：《Signal Transduction and Targeted Therapy》2023年第6期2481-2484,共4页信号转导与靶向治疗（英文）

基　　金：research funding from Guangzhou Women and Children Medical Center,the National Key Research and Development Program of China(2018YFA0107200);National Natural Science Foundation of China(81730005 and 31771616);Macao FDCT(FDCT 0106/2021/A)。

摘　　要：Dear Editor,Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is an enveloped positive-sense single-stranded RNA(ssRNA)virus responsible for the global COVID-19 pandemic.Although vaccines for SARS-CoV-2 have been developed and applied worldwide,research on vaccine adjuvant is lacking.Viral infections normally elicit a range of innate immune responses through the activation of pattern recognition receptors(PRRs).

关 键 词：IMMUNITY VACCINE PATTERN 

分 类 号：R563.1[医药卫生—呼吸系统]